FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Inovio BioMedical

Inovio gets DNA vaccine grant from DoD

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!


The Department of Defense has granted Inovio Pharmaceuticals a Small Business Innovation Research Grant to develop a system that would deliver DNA vaccines by intradermal electroporation simultaneously to two or more spatially distinct sites on the body. That approach, the DoD hopes, would avoid potential immune interference that may result from formulating a dual vaccine. Financial details were not disclosed.

Inovio is developing its electroporation delivery platform, a painless, transdermal approach to administering DNA vaccines using a millisecond electrical pulse. Final testing of the technology will involve delivery of Lassa and Hantaan virus vaccines at the same time in two separate sites on the body. The funding will help Inovio test how far apart the two vaccines must be in order to avoid immune interference.

"This device would provide a means to painlessly deliver multiple vaccines simultaneously, bringing improved protection against infectious diseases to both military and civilian populations, said CEO Dr. J. Joseph Kim in a statement. "This collaboration builds on Inovio's strong relationship with the U.S. Department of Defense, in which Inovio is bringing medical innovation to multiple bio-defense projects."

- here's the Inovio release

Related Articles:
Inovio positive DNA vax results published
Inovio shares jump (again) on vax research pact
Inovio shares soar again on NIH vax research pact

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment
More stories about Inovio BioMedical  


Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

This question is for testing whether you are a human visitor and to prevent automated spam submissions.